Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fimmu.2020.01439 http://scihub22266oqcxt.onion/10.3389/fimmu.2020.01439 32655577!7324709!32655577     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Front+Immunol 2020 ; 11 (ä): 1439 Nephropedia Template TP {{tp|p=32655577|t=2020. Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients |pdf=|usr=}}{{32655577}} gab.com Text Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients JO: Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=32655577 #FOAvip In December 2019, following a cluster of pneumonia cases in China caused by a novel coronavirus (CoV), named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the infection disseminated worldwide and, on March 11th, 2020, the World Health Organization officially declared the pandemic of the relevant disease named coronavirus disease 2019 (COVID-19). In Europe, Italy was the first country facing a true health policy emergency, and, as at 6.00 p.m. on May 2nd, 2020, there have been more than 209,300 confirmed cases of COVID-19. Due to the increasing number of patients experiencing a severe outcome, global scientific efforts are ongoing to find the most appropriate treatment. The usefulness of specific anti-rheumatic drugs came out as a promising treatment option together with antiviral drugs, anticoagulants, and symptomatic and respiratory support. For this reason, we feel a duty to share our experience and our knowledge on the use of these drugs in the immune-rheumatologic field, providing in this review the rationale for their use in the COVID-19 pandemic. Twit Text FOAVip Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients ????Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=32655577 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32655577 #FOAvip English Wikipedia <ref>{{Cite pmid|32655577}}</ref> Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients #MMPMID32655577 Colafrancesco S; Scrivo R; Barbati C; Conti F; Priori R Front Immunol 2020[]; 11 (ä): 1439 PMID32655577show ga In December 2019, following a cluster of pneumonia cases in China caused by a novel coronavirus (CoV), named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the infection disseminated worldwide and, on March 11th, 2020, the World Health Organization officially declared the pandemic of the relevant disease named coronavirus disease 2019 (COVID-19). In Europe, Italy was the first country facing a true health policy emergency, and, as at 6.00 p.m. on May 2nd, 2020, there have been more than 209,300 confirmed cases of COVID-19. Due to the increasing number of patients experiencing a severe outcome, global scientific efforts are ongoing to find the most appropriate treatment. The usefulness of specific anti-rheumatic drugs came out as a promising treatment option together with antiviral drugs, anticoagulants, and symptomatic and respiratory support. For this reason, we feel a duty to share our experience and our knowledge on the use of these drugs in the immune-rheumatologic field, providing in this review the rationale for their use in the COVID-19 pandemic. |Adaptive Immunity/drug effects[MESH] |Adult[MESH] |Anticoagulants/therapeutic use[MESH] |Antirheumatic Agents/therapeutic use[MESH] |Antiviral Agents/therapeutic use[MESH] |Betacoronavirus/immunology/*metabolism[MESH] |COVID-19[MESH] |Cardiovascular Diseases/*drug therapy/*etiology[MESH] |Coronavirus Infections/*complications/*drug therapy/immunology/virology[MESH] |Humans[MESH] |Hydroxychloroquine/therapeutic use[MESH] |Immunity, Innate/drug effects[MESH] |Interleukin-1/antagonists & inhibitors[MESH] |Interleukin-6/antagonists & inhibitors[MESH] |Janus Kinase Inhibitors/therapeutic use[MESH] |Pandemics[MESH] |Pneumonia, Viral/*complications/*drug therapy/immunology/virology[MESH] |Respiratory Distress Syndrome/drug therapy/etiology[MESH]Targeting the Immune System for Pulmonary Inflammation and Cardiovascu(epmc).pdf DeepDyve Pubget Overpricing